These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 7057343)

  • 21. Esomeprazole therapy for gastric acid hypersecretion in children with cystinosis.
    Dohil R; Fidler M; Barshop B; Newbury R; Sellers Z; Deutsch R; Schneider J
    Pediatr Nephrol; 2005 Dec; 20(12):1786-93. PubMed ID: 16133039
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clearance of corneal crystals in nephropathic cystinosis by topical cysteamine 0.5%.
    Jones NP; Postlethwaite RJ; Noble JL
    Br J Ophthalmol; 1991 May; 75(5):311-2. PubMed ID: 2036352
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Phase 1 Pharmacokinetic Study of Cysteamine Bitartrate Delayed-Release Capsules Following Oral Administration with Orange Juice, Water, or Omeprazole in Cystinosis.
    Armas D; Holt RJ; Confer NF; Checani GC; Obaidi M; Xie Y; Brannagan M
    Adv Ther; 2018 Feb; 35(2):199-209. PubMed ID: 29411268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of topical cysteamine in nephropathic cystinosis.
    Al-Hemidan A; Shoughy SS; Kozak I; Tabbara KF
    Br J Ophthalmol; 2017 Sep; 101(9):1234-1237. PubMed ID: 28057644
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pyroglutamic aciduria and nephropathic cystinosis.
    Rizzo C; Ribes A; Pastore A; Dionisi-Vici C; Greco M; Rizzoni G; Federici G
    J Inherit Metab Dis; 1999 May; 22(3):224-6. PubMed ID: 10384373
    [No Abstract]   [Full Text] [Related]  

  • 26. [Quality of life improves].
    Sankawa J
    MMW Fortschr Med; 2015 Jul; 157(13):80. PubMed ID: 26206052
    [No Abstract]   [Full Text] [Related]  

  • 27. Successful use of topical cysteamine formulated from the oral preparation in a child with keratopathy secondary to cystinosis.
    Khan AO; Latimer B
    Am J Ophthalmol; 2004 Oct; 138(4):674-5. PubMed ID: 15488810
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of cystinosis with cysteamine. A pilot study determining dose and form of application.
    Bergonzi E; Herren A; Lavanchy P; Bühlmann C; Wyss SR; Lüthy C; Oetliker O
    Helv Paediatr Acta; 1981 Nov; 36(5):437-43. PubMed ID: 7031022
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Removal of corneal crystals by topical cysteamine in nephropathic cystinosis.
    Kaiser-Kupfer MI; Fujikawa L; Kuwabara T; Jain S; Gahl WA
    N Engl J Med; 1987 Mar; 316(13):775-9. PubMed ID: 3821824
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolism of pantethine in cystinosis.
    Wittwer CT; Gahl WA; Butler JD; Zatz M; Thoene JG
    J Clin Invest; 1985 Oct; 76(4):1665-72. PubMed ID: 4056044
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nephropathic cystinosis in children: An overlooked disease.
    Soliman NA; El-Baroudy R; Rizk A; Bazaraa H; Younan A
    Saudi J Kidney Dis Transpl; 2009 May; 20(3):436-42. PubMed ID: 19414947
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nephropathic cystinosis: posterior segment manifestations and effects of cysteamine therapy.
    Tsilou ET; Rubin BI; Reed G; Caruso RC; Iwata F; Balog J; Gahl WA; Kaiser-Kupfer MI
    Ophthalmology; 2006 Jun; 113(6):1002-9. PubMed ID: 16603246
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravenous cysteamine therapy for nephropathic cystinosis.
    Gahl WA; Ingelfinger J; Mohan P; Bernardini I; Hyman PE; Tangerman A
    Pediatr Res; 1995 Oct; 38(4):579-84. PubMed ID: 8559613
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management dilemmas in pediatric nephrology: Cystinosis.
    Besouw MT; Van Dyck M; Cassiman D; Claes KJ; Levtchenko EN
    Pediatr Nephrol; 2015 Aug; 30(8):1349-60. PubMed ID: 25956701
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improved renal function in children with cystinosis treated with cysteamine.
    Markello TC; Bernardini IM; Gahl WA
    N Engl J Med; 1993 Apr; 328(16):1157-62. PubMed ID: 8455682
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Corneal crystals in nephropathic cystinosis: natural history and treatment with cysteamine eyedrops.
    Gahl WA; Kuehl EM; Iwata F; Lindblad A; Kaiser-Kupfer MI
    Mol Genet Metab; 2000; 71(1-2):100-20. PubMed ID: 11001803
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Halitosis in cystinosis patients after administration of immediate-release cysteamine bitartrate compared to delayed-release cysteamine bitartrate.
    Besouw M; Tangerman A; Cornelissen E; Rioux P; Levtchenko E
    Mol Genet Metab; 2012 Sep; 107(1-2):234-6. PubMed ID: 22832073
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NIH conference. Cystinosis: progress in a prototypic disease.
    Gahl WA; Thoene JG; Schneider JA; O'Regan S; Kaiser-Kupfer MI; Kuwabara T
    Ann Intern Med; 1988 Oct; 109(7):557-69. PubMed ID: 3048161
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo alteration of a mutant human protein using the free thiol cysteamine.
    Gahl WA; Gregg RE; Hoeg JM; Fisher E
    Am J Med Genet; 1985 Feb; 20(2):409-17. PubMed ID: 3976729
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nephropathic cystinosis: ineffectiveness of cysteamine therapy for ocular changes.
    Cantani A; Giardini O; Ciarnella Cantani A
    Am J Ophthalmol; 1983 May; 95(5):713-4. PubMed ID: 6846466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.